Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparative Effectiveness between Expanded Hemodialysis (Hemodialysis Using a Medium Cut-Off Dialyzer) and Mixed-Dilution Online Hemodiafiltration Using a High-Flux Dialyzer in Removing Middle-Molecule Uremic Toxins
Visit resource site
HD
Comparative Effectiveness of Dialyzers: A Longitudinal, Propensity Score-Matched Study of Incident Hemodialysis Patients - Sibbel et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of 2 medium cutoff dialyzers versus on-line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of changes in albumin binding capacity during hemodiafiltration or hemodialysis with middle cut off membranes
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of Circulating Levels of Uremic Toxins in Hemodialysis Patients Treated with Medium Cut-Off Membranes and High-Flux Membranes: Theranova in Sisli Hamidiye Etfal (THE SHE) Randomized Control Study.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of expanded hemodialysis using a medium cut-off dialyzer versus hemodiafiltration: an observational prospective study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of four medium cut-off dialyzers
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of four medium cut-off dialyzers
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of Hemodialysis Using a Medium Cutoff Dialyzer versus Hemodiafiltration: A Controlled Cross-Over Study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of hemodialysis with medium cut-off dialyzer and on-line hemodiafiltration on the removal of small and middle-sized molecules
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of high flux hemodialyzers with medium cut-off dialyzer on the removal of middle high size uremic toxins
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.